Home
Storia in 1 fonti
Dupilumab therapy improves height, bone density for children with eczema
Dupilumab treatment was associated with improved bone growth and bone mineral density in children with eczema, according to a study published in the Journal of the American Academy of Dermatology. Among children aged 6 to 11 years who were below the 40th height percentile at baseline, 31.3% saw a 5 or greater percentile increase 16 weeks after initiating dupilumab (Dupixent; Sanofi, Regeneron).
Raccontata da
healio.com
Timeline cronologica
- ·
Dupilumab shows benefits in infants with EoE not meeting approval thresholds
Among infants with eosinophilic esophagitis aged younger than 1 year or weighing less than 15 kg, esophageal eosinophilia and growth improved after starting dupilumab, according…
- ·
Dupilumab therapy improves height, bone density for children with eczema
Dupilumab treatment was associated with improved bone growth and bone mineral density in children with eczema, according to a study published in the Journal of the American…